Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Molecular Profile | PALB2 Y1108fs |
Therapy | Talazoparib |
Indication/Tumor Type | nephroblastoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PALB2 Y1108fs | nephroblastoma | sensitive | Talazoparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a Wilms tumor cell line and xenograft model harboring PALB2 Y1108fs demonstrated a complete response to Talzenna (talazoparib) (PMID: 25263539). | 25263539 |
PubMed Id | Reference Title | Details |
---|---|---|
(25263539) | Initial testing (stage 1) of the PARP inhibitor BMN 673 by the pediatric preclinical testing program: PALB2 mutation predicts exceptional in vivo response to BMN 673. | Full reference... |